30 results on '"Feagan, B. G."'
Search Results
2. OP033 The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: results from the tofacitinib ulcerative colitis clinical programme
3. Supplement to: Ozanimod induction and maintenance treatment for ulcerative colitis.
4. Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohnʼs disease
5. Review article: dose optimisation of infliximab for acute severe ulcerative colitis
6. Effects of vedolizumab on health‐related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial
7. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials
8. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases
9. Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohnʼs disease
10. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis
11. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohnʼs disease
12. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohnʼs disease activity
13. Letter: limitations of studies to evaluate the significance of anti-tumour necrosis factor serum levels in Crohnʼs disease – authorsʼ reply
14. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohnʼs disease
15. Review article: a clinicianʼs guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease
16. Evaluation of a daily practice composite score for the assessment of Crohnʼs disease: the treatment impact of certolizumab pegol
17. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn’s disease with prior loss of response to infliximab
18. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohnʼs disease in the PRECiSE 2 study
19. Medical management of mild to moderate Crohnʼs disease: evidence-based treatment algorithms for induction and maintenance of remission
20. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial
21. CDP571, a humanized monoclonal antibody to tumour necrosis factor-α, for steroid-dependent Crohnʼs disease: a randomized, double-blind, placebo-controlled trial
22. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-α, in patients with corticosteroid-dependent Crohnʼs disease
23. CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial
24. Mild to moderate Crohnʼs disease – defining the basis for a new treatment algorithm
25. Systematic review: the effectiveness of budesonide therapy for Crohnʼs disease
26. Transfusion practice in elective orthopaedic surgery
27. Review article: economic issues in Crohn's disease - assessing the effects of new treatments on health-related quality of life
28. Review article: Drug development in inflammatory bowel disease: budesonide-a model of targeted therapy
29. A Randomized Study Comparing Patient-Directed Hypertension Management with Usual Office-Based Care: PIII-58
30. Oral Budesonide is Effective In Active Crohnʼs Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.